Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors-Reference-Cited by-同舟云学术

Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors

Published:2022-10 Issue:5 Volume:7 Page:100576
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Le Tourneau C.,Becker H.,Claus R.,Elez E.,Ricci F.,Fritsch R.,Silber Y.,Hennequin A.,Tabernero J.,Jayadeva G.,Luedtke D.,He M.,Isambert N.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference30 articles.

1. Tumor angiogenesis and anti-angiogenic gene therapy for cancer;Li;Oncol Lett,2018

2. Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales;El-Kenawi;Br J Pharmacol,2013

3. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges;Fukumura;Nat Rev Clin Oncol,2018

4. Bevacizumab (avastin) in cancer treatment: a review of 15 years of clinical experience and future outlook;Garcia;Cancer Treat Rev,2020

5. Aflibercept: a review in metastatic colorectal cancer;Syed;Drugs,2015

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor Inhibitors in Health and Disease;Pharmaceuticals;2024-07-18

2. Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses;Journal of Nanobiotechnology;2024-05-31

3. Beyond binary: bridging neutrophil diversity to new therapeutic approaches in NSCLC;Trends in Cancer;2024-05

4. Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions;mAbs;2024-04-26

5. The role of vasculature and angiogenesis in respiratory diseases;Angiogenesis;2024-04-05